These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

551 related articles for article (PubMed ID: 31528850)

  • 1. Two-way mobile phone intervention compared with standard-of-care adherence support after second-line antiretroviral therapy failure: a multinational, randomised controlled trial.
    Gross R; Ritz J; Hughes MD; Salata R; Mugyenyi P; Hogg E; Wieclaw L; Godfrey C; Wallis CL; Mellors JW; Mudhune VO; Badal-Faesen S; Grinsztejn B; Collier AC
    Lancet Digit Health; 2019 May; 1(1):e26-e34. PubMed ID: 31528850
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of a mobile phone short message service on antiretroviral treatment adherence in Kenya (WelTel Kenya1): a randomised trial.
    Lester RT; Ritvo P; Mills EJ; Kariri A; Karanja S; Chung MH; Jack W; Habyarimana J; Sadatsafavi M; Najafzadeh M; Marra CA; Estambale B; Ngugi E; Ball TB; Thabane L; Gelmon LJ; Kimani J; Ackers M; Plummer FA
    Lancet; 2010 Nov; 376(9755):1838-45. PubMed ID: 21071074
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial.
    Ciaffi L; Koulla-Shiro S; Sawadogo AB; Ndour CT; Eymard-Duvernay S; Mbouyap PR; Ayangma L; Zoungrana J; Gueye NFN; Diallo M; Izard S; Bado G; Kane CT; Aghokeng AF; Peeters M; Girard PM; Le Moing V; Reynes J; Delaporte E;
    Lancet HIV; 2017 Sep; 4(9):e384-e392. PubMed ID: 28566227
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Randomized Controlled Trial of Real-Time Electronic Adherence Monitoring With Text Message Dosing Reminders in People Starting First-Line Antiretroviral Therapy.
    Orrell C; Cohen K; Mauff K; Bangsberg DR; Maartens G; Wood R
    J Acquir Immune Defic Syndr; 2015 Dec; 70(5):495-502. PubMed ID: 26218411
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of mobile telephone reminders on treatment outcome in HIV: evidence from a randomised controlled trial in India.
    Shet A; De Costa A; Kumarasamy N; Rodrigues R; Rewari BB; Ashorn P; Eriksson B; Diwan V;
    BMJ; 2014 Oct; 349():g5978. PubMed ID: 25742320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mobile phone text messaging for promoting adherence to antiretroviral therapy in patients with HIV infection.
    Horvath T; Azman H; Kennedy GE; Rutherford GW
    Cochrane Database Syst Rev; 2012 Mar; 2012(3):CD009756. PubMed ID: 22419345
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Partner-based adherence intervention for second-line antiretroviral therapy (ACTG A5234): a multinational randomised trial.
    Gross R; Zheng L; La Rosa A; Sun X; Rosenkranz SL; Cardoso SW; Ssali F; Camp R; Godfrey C; Cohn SE; Robbins GK; Chisada A; Wallis CL; Reynolds NR; Lu D; Safren SA; Hosey L; Severe P; Collier AC;
    Lancet HIV; 2015 Jan; 2(1):e12-9. PubMed ID: 26424232
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BREATHER (PENTA 16) short-cycle therapy (SCT) (5 days on/2 days off) in young people with chronic human immunodeficiency virus infection: an open, randomised, parallel-group Phase II/III trial.
    Butler K; Inshaw J; Ford D; Bernays S; Scott K; Kenny J; Klein N; Turkova A; Harper L; Nastouli E; Paparini S; Choudhury R; Rhodes T; Babiker A; Gibb D
    Health Technol Assess; 2016 Jun; 20(49):1-108. PubMed ID: 27377073
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trial.
    Amuge P; Lugemwa A; Wynne B; Mujuru HA; Violari A; Kityo CM; Archary M; Variava E; White E; Turner RM; Shakeshaft C; Ali S; Nathoo KJ; Atwine L; Liberty A; Bbuye D; Kaudha E; Mngqibisa R; Mosala M; Mumbiro V; Nanduudu A; Ankunda R; Maseko L; Kekitiinwa AR; Giaquinto C; Rojo P; Gibb DM; Turkova A; Ford D;
    Lancet HIV; 2022 Sep; 9(9):e638-e648. PubMed ID: 36055295
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rates of viral suppression in a cohort of people with stable HIV from two community models of ART delivery versus facility-based HIV care in Lusaka, Zambia: a cluster-randomised, non-inferiority trial nested in the HPTN 071 (PopART) trial.
    Limbada M; Macleod D; Situmbeko V; Muhau E; Shibwela O; Chiti B; Floyd S; Schaap AJ; Hayes R; Fidler S; Ayles H;
    Lancet HIV; 2022 Jan; 9(1):e13-e23. PubMed ID: 34843674
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the management of pretreatment HIV drug resistance by oligonucleotide ligation assay: a randomised controlled trial.
    Chung MH; McGrath CJ; Beck IA; Levine M; Milne RS; So I; Andersen N; Dross S; Coombs RW; Chohan B; Yatich N; Kiptinness C; Sakr SR; Kiarie JN; Frenkel LM
    Lancet HIV; 2020 Feb; 7(2):e104-e112. PubMed ID: 31818716
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mobile Text Messaging to Improve Medication Adherence and Viral Load in a Vulnerable Canadian Population Living With Human Immunodeficiency Virus: A Repeated Measures Study.
    King E; Kinvig K; Steif J; Qiu AQ; Maan EJ; Albert AY; Pick N; Alimenti A; Kestler MH; Money DM; Lester RT; Murray MCM
    J Med Internet Res; 2017 Jun; 19(6):e190. PubMed ID: 28572079
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the SECOND-LINE trial: an exploratory analysis.
    Boyd MA; Moore CL; Molina JM; Wood R; Madero JS; Wolff M; Ruxrungtham K; Losso M; Renjifo B; Teppler H; Kelleher AD; Amin J; Emery S; Cooper DA;
    Lancet HIV; 2015 Feb; 2(2):e42-51. PubMed ID: 26424460
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of mobile text messages on antiretroviral medication adherence and patient retention in early HIV care: an open-label, randomized, single center study in south Florida.
    Sherman EM; Niu J; Elrod S; Clauson KA; Alkhateeb F; Eckardt P
    AIDS Res Ther; 2020 May; 17(1):16. PubMed ID: 32404130
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Switch to second-line versus continued first-line antiretroviral therapy for patients with low-level HIV-1 viremia: An open-label randomized controlled trial in Lesotho.
    Amstutz A; Nsakala BL; Vanobberghen F; Muhairwe J; Glass TR; Namane T; Mpholo T; Battegay M; Klimkait T; Labhardt ND
    PLoS Med; 2020 Sep; 17(9):e1003325. PubMed ID: 32936795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase 3 FLAIR study.
    Orkin C; Bernal Morell E; Tan DHS; Katner H; Stellbrink HJ; Belonosova E; DeMoor R; Griffith S; Thiagarajah S; Van Solingen-Ristea R; Ford SL; Crauwels H; Patel P; Cutrell A; Smith KY; Vandermeulen K; Birmingham E; St Clair M; Spreen WR; D'Amico R
    Lancet HIV; 2021 Nov; 8(11):e668-e678. PubMed ID: 34656207
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Implementation of an intensive adherence intervention in patients with second-line antiretroviral therapy failure in four west African countries with little access to genotypic resistance testing: a prospective cohort study.
    Eholie SP; Moh R; Benalycherif A; Gabillard D; Ello F; Messou E; Zoungrana J; Diallo I; Diallo M; Bado G; Cisse M; Maiga AI; Anzian A; Toni TD; Congo-Ouedraogo M; Toure-Kane C; Seydi M; Minta DK; Sawadogo A; Sangaré L; Drabo J; Karcher S; Le Carrou J; de Monteynard LA; Peytavin G; Gabassi A; Girard PM; Chaix ML; Anglaret X; Landman R;
    Lancet HIV; 2019 Nov; 6(11):e750-e759. PubMed ID: 31601544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Cameroon Mobile Phone SMS (CAMPS) trial: a randomized trial of text messaging versus usual care for adherence to antiretroviral therapy.
    Mbuagbaw L; Thabane L; Ongolo-Zogo P; Lester RT; Mills EJ; Smieja M; Dolovich L; Kouanfack C
    PLoS One; 2012; 7(12):e46909. PubMed ID: 23236345
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Uptake of antiretroviral therapy and male circumcision after community-based HIV testing and strategies for linkage to care versus standard clinic referral: a multisite, open-label, randomised controlled trial in South Africa and Uganda.
    Barnabas RV; van Rooyen H; Tumwesigye E; Brantley J; Baeten JM; van Heerden A; Turyamureeba B; Joseph P; Krows M; Thomas KK; Schaafsma TT; Hughes JP; Celum C
    Lancet HIV; 2016 May; 3(5):e212-20. PubMed ID: 27126488
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of HIV-1 low-level viraemia during antiretroviral therapy on treatment outcomes in WHO-guided South African treatment programmes: a multicentre cohort study.
    Hermans LE; Moorhouse M; Carmona S; Grobbee DE; Hofstra LM; Richman DD; Tempelman HA; Venter WDF; Wensing AMJ
    Lancet Infect Dis; 2018 Feb; 18(2):188-197. PubMed ID: 29158101
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.